Southern Cross Pharma Ltd v Euro-Celtique S.A

Link copied
Case Copied 13 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 44

Patent No.:2002300863, 2009243527

Title:Controlled Release Formulation

Patentee:  Euro-Celtique S.A.

Opponent:  Southern Cross Pharma Pty Ltd

Hearing Officer:  P M Spann, Deputy Commissioner of Patents

Decision Date:  6 July 2016

Hearing Date:  19 May 2016 by written submissions

Catchwords:  PATENTS – reg 4.3(2)(b) – whether there are reasonable grounds for believing that evidence proposed to be filed should not be open to public inspection – order made  – inspection allowed subject to undertakings as to confidentiality.

Representation:  Patentee: Philip Kerr, solicitor, and Linda Govenlock of Allens Patent & Trade Mark Attorneys, Sydney.

Opponent: Kate Beattie, counsel, instructed by Duncan Bucknell Company.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Nos.:2002300863, 2009243527

Title:Controlled Release Formulation

Patentee:  Euro-Celtique S.A.

Date of Decision:  6 July 2016

DECISION

I direct that:

a)Evidence of the weight for weight proportions (% w/w) of cellulose ether and polyalkylene glycol(s), and of hydrophilic or hydrophobic polymer(s), as these occur in the goods TRAMAL® SR 100, when filed, is not Open to Public Inspection (OPI);

b)The period in which the evidence is to be filed in response to the delegate’s direction in Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 1 is extended to 1 month from the date of this decision; and

c)The non-OPI evidence is available for inspection by the opponent’s Australian legal representatives on them giving undertakings to the patentee that the information contained in the evidence will be used only in relation to the present opposition and not be disclosed to any other person.

REASONS FOR DECISION

  1. This matter concerns whether there are reasonable grounds for believing that evidence proposed to be filed in the opposition should not be open to public inspection. It is to be determined under the Patents Regulations as amended on 15 April 2013 by the Intellectual Property Legislation Amendment (Raising the Bar) Regulation 2013 (No 1).

    BACKGROUND

  2. On 7 May 2014, Euro-Celtique S.A. (the patentee) applied for extensions of the term of related patents 2002300863 (‘863), 2004229058 (‘058) and 2009243527 (‘527). The date of these patents is 9 May 1994 and their maximum 20-year term expired on 9 May 2014. If extensions are granted the term of each patent would instead expire on 21 September 2015.

  1. On 10 September 2014, Southern Cross Pharma Pty Ltd (the opponent) filed notices under s 75 opposing grant of the extensions. The oppositions were heard and on 8 January 2016 the delegate in Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 1 decided that the opposition to ‘058 was unsuccessful (and the extension has been granted) but upheld oppositions to ‘863 and ‘527. Nevertheless she provided the opportunity for the patentee to provide further information in support of these applications:

    (i)for the 2009243527 patent, more precise information regarding the weight for weight proportions (% w/w) of cellulose ether and polyalkylene glycol(s) as these occur in the goods TRAMAL® SR 100, and

    (ii) for the 2002300863 patent, precise information…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Southern Cross Pharma Ltd v Euro-Celtique S.A and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] APO 44
Decision Date

CaseChat Overview and Summary

In the matter of Southern Cross Pharma Ltd v Euro-Celtique S.A, the dispute centred on whether specific information regarding the composition of the pharmaceutical product TRAMAL® SR 100 should be exempt from public inspection. Euro-Celtique S.A. (the patentee) sought to prevent the disclosure of certain confidential information related to the weight-for-weight proportions of excipients in the product, claiming it was proprietary and confidential. Southern Cross Pharma Pty Ltd (the opponent) opposed this request, arguing that the information was necessary to determine the validity of the patent extension applications. The central legal issue was whether there were reasonable grounds under the Patents Regulations for the proposed evidence to be withheld from public inspection.

The court considered the relevant provisions of the Patents Regulations, which allow for the Commissioner to withhold documents from public inspection if there are reasonable grounds to believe that they should not be disclosed. The decision hinged on whether the information in question posed a real risk of harm if made public. The patentee argued that disclosure would breach its confidentiality obligations to Grunenthal GmbH, provide unfair commercial advantage to competitors, and hinder their ability to present their best case in the opposition proceedings. Conversely, the opponent argued that the information was necessary for transparency and to assess the validity of the patent extension applications.

After weighing the interests, the court concluded that there were reasonable grounds for withholding the information from public inspection. The relationship between the patentee, Mundipharma, and Grunenthal suggested a sensitive and unusual agreement, where the disclosure of the product formulation would likely cause significant commercial harm to Grunenthal. Additionally, the precise formulation of the product was of limited public interest beyond ensuring the link between the product and the patent. The court granted an order to extend the time for filing the information and allowed inspection by the opponent's legal representatives, provided they gave undertakings of confidentiality. This decision balanced the need for transparency in patent opposition proceedings with the protection of proprietary and confidential information.